Stand Up To Cancer - standup2cancer.orgThis is where the end of cancer begins
   Please leave this field empty

SU2C Scientific Research Teams

Share this:
Email

Like this page on Facebook

Levi Garraway, MD, PhD

Scientific Research Team:
Levi Garraway, MD, PhD

Levi Garraway, MD, PhD

The SU2C – National Science Foundation- V Foundation Drug Combination Convergence Translational Research

Levi Garraway, MD, Ph.D, is an Associate Professor of Medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School, and an Institute Member of the Broad Institute. He is the inaugural Director of the Center for Cancer Precision Medicine at Dana-Farber, Brigham and Women’s Hospital, and the Broad Institute.

Garraway received his A.B. in Biochemical Sciences from Harvard College in 1990 and his M.D. and Ph.D. degrees from Harvard Medical School in 1999. He completed his internship and residency in Internal Medicine at the Massachusetts General Hospital, where he served as Chief Resident in 2003. He received fellowship training in Medical Oncology at Dana-Farber Cancer Institute.

Garraway has made seminal research contributions in cancer genomics, drug resistance, and cancer precision medicine. His work has identified multiple new cancer genes and several fundamental mechanisms by which cancer may arise. His contributions have also informed a conceptual framework for understanding resistance mechanisms relevant to many tumor types and identified novel therapeutic avenues for clinical trials. His research has influenced precision medicine initiatives at many cancer centers worldwide and inspired the launch of Foundation Medicine, Inc., a genomics-based cancer diagnostics company co-founded by Garraway.

In 2009, Garraway was inducted into the American Society for Clinical Investigation (ASCI), and he currently serves as ASCI president. He has earned several awards and honors, including the prestigious Outstanding Investigator Award from the National Cancer Institute. Garraway was named a Howard Hughes Medical Institute investigator in 2015.